Phase I Results

Syntopix Group plc
16 August 2007


For immediate release                                           16 August 2007

                               SYNTOPIX GROUP PLC

                         ('Syntopix' or 'the Company')



PHASE I TRIAL RESULTS IN ACNE



Syntopix Group plc (AIM: SYN), the speciality pharmaceutical research and
development company focused on dermatological diseases,  announces the results
of a human use Phase I  trial that validated the Company's methodology for
determining the potential of compounds as topical treatments for acne, with
positive and negative controls performing as expected. The study confirmed the
safety and tolerability of all three test treatments in the skin environment.



All the test treatments exhibited some antibacterial activity, with this
activity sustained throughout the trial in one of the three treatment groups.
Further optimisation work will be required before the test treatments can
proceed to later stages of clinical development.



The Syntopix test treatments were assessed over 14 days in a double-blind,
randomised and controlled trial of 22 healthy volunteers. They were SYN 0017 (an
antioxidant present in foods and cosmetics), SYN 0401 (an antifungal present in
personal healthcare products), and a combination of SYN 0017 and SYN 0016 (an
oxidising agent present in pharmaceutical preparations).



All three treatment groups produced positive safety and tolerability data with
no adverse events being recorded. Additionally, all of the treatments produced a
significant reduction in the number of Propionibacterium acnes (P. acnes) after
four hours. P. acnes is a bacterium associated with acne and was being used in
the trial as a surrogate marker to indicate clinical activity. For one
treatment, four of the seven subjects showed a consistent benefit over the two
weeks of the study.



In addition to further evaluation of these test treatments, Syntopix will
continue to assess other compounds from its library of more than 1100 diverse
compounds for topical treatments for acne.



Stephen Jones, Syntopix' CEO, commented: 'Whilst all the test treatments were
shown to be active in the skin environment, further evaluation and optimisation
work is required to maximise their efficacy. We will also continue to evaluate
other suitable compounds from our extensive library of highly diverse compounds
for the topical treatment of acne.'





Syntopix confirms that the information required by Rule 26 of the AIM Rules for
Companies (February 2007) is available within the Investor Relations section of
the Company's website at http://www.syntopix.com/.











For further information please contact:


Syntopix Group plc                                              0845 125 9204
Stephen Jones, Chief Executive Officer
Rod Adams, Chairman

KBC Peel Hunt Ltd                                               020 7418 8900
Capel Irwin

Buchanan Communications                                         020 7466 5000
Mark Court/Catherine Breen



Notes to editors





About Syntopix Group plc



Syntopix, a group focused on the discovery and development of drugs for the
topical treatment of dermatological diseases. The company was founded in 2003 as
a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of
the leading experts in skin microbiology, with initial funding from The Wellcome
Trust.



Syntopix' strategy is to seek to reduce the risks and costs of drug discovery
and development by discovering novel uses for known compounds. The company
concentrates  on compounds and combinations of compounds that have a history of
safe use in man; and that have well characterised  properties, for example
antimicrobials and anti-inflammatories. The Group currently has 10 pending UK
patent applications.



Syntopix is currently concentrating on acne and Staphylococcus aureus infections
and has identified a pipeline of lead drug candidates that it intends to take
through pre-clinical and, as appropriate, clinical trials. The Group intends to
out-license products to commercial partners on obtaining proof of principle and
to seek co-development partnerships.



The Group is based at the Institute of Pharmaceutical Innovation in Bradford,
giving access to the expertise in skin biology, formulation and toxicology at
the universities of Bradford and Leeds.



Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group
plc), The Wellcome Trust Limited, University of Leeds Limited, White Rose
Technology Limited and Ridings Early Growth Investment Company Limited.
Syntopix joined the AIM market of the London Stock Exchange in March 2006.



For further information please visit www.syntopix.com.








                      This information is provided by RNS
            The company news service from the London Stock Exchange